Who we are

We see a future where sequencing generates more information from DNA and is achievable at far lower costs, bringing closer the day when advanced medicines, diagnostics and personalized treatments become a reality for all.

Cambridge Epigenetix (CEGX) is a life sciences tools and analytics company that has created a technology platform delivering step changes in both the type of information that can be generated from DNA and the cost at which it is gathered.

Our Team

Leadership

Gail Marcus

Chair of the Board

Professor Sir Shankar Balasubramanian FRS

Founder

Dr. Joanna Holbrook

Senior Vice President of Research

Fiona Stewart

Chief Financial Officer

Dr. Philippa Burns

Director of Research & Development

Dr. Páidí Creed

Director of AI, Bioinformatics and Software

Manuela Morgan

Head of Human Resources

Scientific Advisors

Professor Sir Shankar Balasubramanian FRS

Founder

Professor Wolf Reik

Head of the Epigenetics Programme, Babraham Institute

Professor Anjana Rao

Head of the Division of Signalling and Gene Expression, La Jolla Institute

Professor Mark Dawson

Group Leader of the Cancer Epigenetics Laboratory, Peter MacCallum Cancer Centre

Rahul Kohli

Associate Professor of Medicine and Biochemistry & Biophysics, Penn Epigenetics Institute, University of Pennsylvania (UPenn)

Board

Gail Marcus

Acting CEO

Dr. Bobby Yerramilli-Rao

Co-Founder

Professor Sir Shankar Balasubramanian FRS

Founder

Tom Hulme

General Partner, GV

Alice Newcombe-Ellis

Managing Partner, Ahren Innovation Capital

Somu Subramaniam

Managing Partner, New Science Ventures

Roelof F. Botha

Managing Partner, Sequoia Capital

Investors

Ahren

Syncona

GV

New Science Ventures

Sequoia Capital